CIMEIO develops game changing immunotherapies for leukemic tumors, non-malignant blood disorders, auto-immune diseases and tolerance for organ transplantation. This is achieved by “resetting the immune system” by eliminating diseased and healthy hematopietic stem cells (HSCs) utilizing CART-cells or monoclonal antibodies (mAb) and reconstituing the hematopietic system with allele engineered, “shielded” donor HCSs. HSCs are shielded against CART-cell or mAb attack by introducing a point mutation to a specific cell receptor.
Cimeio Therapeutics
